Emily A Largent1, Twisha Bhardwaj2, Maramawit Abera3, Shana D Stites4, Kristin Harkins3, Alan J Lerner5, Angela R Bradbury1,3, Jason Karlawish1,3,6. 1. Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 2. Dartmouth College, Hanover, NH, USA. 3. Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 4. Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 5. Brain Health and Memory Center, University Hospitals Cleveland Medical Center, Cleveland, OH, USA. 6. Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Abstract
BACKGROUND: Current practice guidelines recommend against Apolipoprotein E (APOE) testing. However, advances in Alzheimer's disease (AD) research and care may soon change this. OBJECTIVE: To examine longitudinally the experience of learning an APOE result and, if an ɛ4 carrier, taking a disease-specific treatment to reduce one's risk of AD. METHODS: Fifty ɛ4 carriers and 20 non-carriers completed semi-structured interviews 3 months and 15 months after APOE disclosure. RESULTS: Individuals generally understand their APOE results. While non-carriers felt relief, ɛ4 carriers often described themselves as disappointed by their result but nevertheless glad to know. Carriers expressed concerns about stigma and discrimination, including in the workplace. Carriers adopted new health behaviors at higher rates than non-carriers and revised their future plans to account for their increased risk of AD. Individuals participating in research were hopeful that their participation would help them or others; individuals who learned they were at increased risk for AD but who could not participate in research were disappointed. CONCLUSION: Providers disclosing APOE results should be sensitive to how APOE results shape emotions, self-perceptions, and attitudes about memory; raise concerns about stigma and discrimination in personal and professional relationships; influence health behaviors and decision-making; and can have follow-on effects on family members.
BACKGROUND: Current practice guidelines recommend against Apolipoprotein E (APOE) testing. However, advances in Alzheimer's disease (AD) research and care may soon change this. OBJECTIVE: To examine longitudinally the experience of learning an APOE result and, if an ɛ4 carrier, taking a disease-specific treatment to reduce one's risk of AD. METHODS: Fifty ɛ4 carriers and 20 non-carriers completed semi-structured interviews 3 months and 15 months after APOE disclosure. RESULTS: Individuals generally understand their APOE results. While non-carriers felt relief, ɛ4 carriers often described themselves as disappointed by their result but nevertheless glad to know. Carriers expressed concerns about stigma and discrimination, including in the workplace. Carriers adopted new health behaviors at higher rates than non-carriers and revised their future plans to account for their increased risk of AD. Individuals participating in research were hopeful that their participation would help them or others; individuals who learned they were at increased risk for AD but who could not participate in research were disappointed. CONCLUSION: Providers disclosing APOE results should be sensitive to how APOE results shape emotions, self-perceptions, and attitudes about memory; raise concerns about stigma and discrimination in personal and professional relationships; influence health behaviors and decision-making; and can have follow-on effects on family members.
Authors: P J Neumann; J K Hammitt; C Mueller; H M Fillit; J Hill; N A Tetteh; K S Kosik Journal: Health Aff (Millwood) Date: 2001 Sep-Oct Impact factor: 6.301
Authors: Serena Chao; J Scott Roberts; Theresa M Marteau; Rebecca Silliman; L Adrienne Cupples; Robert C Green Journal: Alzheimer Dis Assoc Disord Date: 2008 Jan-Mar Impact factor: 2.703
Authors: Jing Qian; Frank J Wolters; Alexa Beiser; Mary Haan; M Arfan Ikram; Jason Karlawish; Jessica B Langbaum; John M Neuhaus; Eric M Reiman; J Scott Roberts; Sudha Seshadri; Pierre N Tariot; Beth McCarty Woods; Rebecca A Betensky; Deborah Blacker Journal: PLoS Med Date: 2017-03-21 Impact factor: 11.069
Authors: Jennifer G Goldman; Beth A Vernaleo; Richard Camicioli; Nabila Dahodwala; Roseanne D Dobkin; Terry Ellis; James E Galvin; Connie Marras; Jerri Edwards; Julie Fields; Robyn Golden; Jason Karlawish; Bonnie Levin; Lisa Shulman; Glenn Smith; Christine Tangney; Cathi A Thomas; Alexander I Tröster; Ergun Y Uc; Noreen Coyan; Crystal Ellman; Mike Ellman; Charlie Hoffman; Susan Hoffman; Don Simmonds Journal: NPJ Parkinsons Dis Date: 2018-06-26
Authors: J Cummings; G D Rabinovici; A Atri; P Aisen; L G Apostolova; S Hendrix; M Sabbagh; D Selkoe; M Weiner; S Salloway Journal: J Prev Alzheimers Dis Date: 2022